Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen

L. Ereshefsky, Stephen R Saklad, T. Tran-Johnson, G. Toney, R. C. Lyman, C. M. Davis

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We have evaluated the efficacy and safety of different dosing regimens of haloperidol decanoate (HLD). Eighteen patients were evaluated as part of our ongoing Therapeutic Drug Monitoring Program. Diagnoses were chronic schizophrenia (n = 12), bipolar with psychosis (n = 3), and others (n = 3). Patients were assessed prior to each HLD dose using the Clinical Global Impressions (CGI) rating scale. The total monthly HLD dose for our population was calculated based on a target conversion ratio of 20 times the previously administered oral haloperidol dose given in divided doses of 100 mg to 150 mg every 3 to 7 days until the full amount was administered. This HLD dosing pattern was repeated during the second month, but at a lower dose to compensate for drug accumulation. Despite this loading dose paradigm, significantly greater haloperidol plasma concentrations were present during oral haloperidol than during the first month of HLD therapy. This regimen achieves therapeutically equivalent plasma concentrations (Cps) more rapidly following conversion from oral haloperidol than standard dosing procedures. A series of cases and pharmacokinetic simulations are used to illustrate the therapeutic relationship of dosing to plasma concentrations.

Original languageEnglish (US)
Pages (from-to)108-114
Number of pages7
JournalPsychopharmacology Bulletin
Volume26
Issue number1
StatePublished - 1990

Fingerprint

Haloperidol
Drug Monitoring
Psychotic Disorders
Schizophrenia
Pharmacokinetics
haloperidol decanoate
Safety
Therapeutics
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology

Cite this

Ereshefsky, L., Saklad, S. R., Tran-Johnson, T., Toney, G., Lyman, R. C., & Davis, C. M. (1990). Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen. Psychopharmacology Bulletin, 26(1), 108-114.

Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen. / Ereshefsky, L.; Saklad, Stephen R; Tran-Johnson, T.; Toney, G.; Lyman, R. C.; Davis, C. M.

In: Psychopharmacology Bulletin, Vol. 26, No. 1, 1990, p. 108-114.

Research output: Contribution to journalArticle

Ereshefsky, L, Saklad, SR, Tran-Johnson, T, Toney, G, Lyman, RC & Davis, CM 1990, 'Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen', Psychopharmacology Bulletin, vol. 26, no. 1, pp. 108-114.
Ereshefsky L, Saklad SR, Tran-Johnson T, Toney G, Lyman RC, Davis CM. Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen. Psychopharmacology Bulletin. 1990;26(1):108-114.
Ereshefsky, L. ; Saklad, Stephen R ; Tran-Johnson, T. ; Toney, G. ; Lyman, R. C. ; Davis, C. M. / Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen. In: Psychopharmacology Bulletin. 1990 ; Vol. 26, No. 1. pp. 108-114.
@article{a7fa4c5deb084c8c90ca8d92144b7001,
title = "Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen",
abstract = "We have evaluated the efficacy and safety of different dosing regimens of haloperidol decanoate (HLD). Eighteen patients were evaluated as part of our ongoing Therapeutic Drug Monitoring Program. Diagnoses were chronic schizophrenia (n = 12), bipolar with psychosis (n = 3), and others (n = 3). Patients were assessed prior to each HLD dose using the Clinical Global Impressions (CGI) rating scale. The total monthly HLD dose for our population was calculated based on a target conversion ratio of 20 times the previously administered oral haloperidol dose given in divided doses of 100 mg to 150 mg every 3 to 7 days until the full amount was administered. This HLD dosing pattern was repeated during the second month, but at a lower dose to compensate for drug accumulation. Despite this loading dose paradigm, significantly greater haloperidol plasma concentrations were present during oral haloperidol than during the first month of HLD therapy. This regimen achieves therapeutically equivalent plasma concentrations (Cps) more rapidly following conversion from oral haloperidol than standard dosing procedures. A series of cases and pharmacokinetic simulations are used to illustrate the therapeutic relationship of dosing to plasma concentrations.",
author = "L. Ereshefsky and Saklad, {Stephen R} and T. Tran-Johnson and G. Toney and Lyman, {R. C.} and Davis, {C. M.}",
year = "1990",
language = "English (US)",
volume = "26",
pages = "108--114",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "1",

}

TY - JOUR

T1 - Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen

AU - Ereshefsky, L.

AU - Saklad, Stephen R

AU - Tran-Johnson, T.

AU - Toney, G.

AU - Lyman, R. C.

AU - Davis, C. M.

PY - 1990

Y1 - 1990

N2 - We have evaluated the efficacy and safety of different dosing regimens of haloperidol decanoate (HLD). Eighteen patients were evaluated as part of our ongoing Therapeutic Drug Monitoring Program. Diagnoses were chronic schizophrenia (n = 12), bipolar with psychosis (n = 3), and others (n = 3). Patients were assessed prior to each HLD dose using the Clinical Global Impressions (CGI) rating scale. The total monthly HLD dose for our population was calculated based on a target conversion ratio of 20 times the previously administered oral haloperidol dose given in divided doses of 100 mg to 150 mg every 3 to 7 days until the full amount was administered. This HLD dosing pattern was repeated during the second month, but at a lower dose to compensate for drug accumulation. Despite this loading dose paradigm, significantly greater haloperidol plasma concentrations were present during oral haloperidol than during the first month of HLD therapy. This regimen achieves therapeutically equivalent plasma concentrations (Cps) more rapidly following conversion from oral haloperidol than standard dosing procedures. A series of cases and pharmacokinetic simulations are used to illustrate the therapeutic relationship of dosing to plasma concentrations.

AB - We have evaluated the efficacy and safety of different dosing regimens of haloperidol decanoate (HLD). Eighteen patients were evaluated as part of our ongoing Therapeutic Drug Monitoring Program. Diagnoses were chronic schizophrenia (n = 12), bipolar with psychosis (n = 3), and others (n = 3). Patients were assessed prior to each HLD dose using the Clinical Global Impressions (CGI) rating scale. The total monthly HLD dose for our population was calculated based on a target conversion ratio of 20 times the previously administered oral haloperidol dose given in divided doses of 100 mg to 150 mg every 3 to 7 days until the full amount was administered. This HLD dosing pattern was repeated during the second month, but at a lower dose to compensate for drug accumulation. Despite this loading dose paradigm, significantly greater haloperidol plasma concentrations were present during oral haloperidol than during the first month of HLD therapy. This regimen achieves therapeutically equivalent plasma concentrations (Cps) more rapidly following conversion from oral haloperidol than standard dosing procedures. A series of cases and pharmacokinetic simulations are used to illustrate the therapeutic relationship of dosing to plasma concentrations.

UR - http://www.scopus.com/inward/record.url?scp=0024996122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024996122&partnerID=8YFLogxK

M3 - Article

C2 - 2371365

AN - SCOPUS:0024996122

VL - 26

SP - 108

EP - 114

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 1

ER -